NASDAQ: NVNOEnvveno Medical Corp Stock
$10.50+0.50 (+5%)
Updated Jun 22, 2026
NVNO Price
$10.50
Fair Value Price
$4.02
Market Cap
$7.01M
52 Week Low
$8.67
52 Week High
$196.70
P/E
-0.33x
P/B
0.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.82M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$15M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NVNO Overview
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVNO's potential to beat the market
- NVNO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NVNO
RankedUnranked of 93
RankedUnranked of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.79 | A | |
| $38.40 | A | |
| $26.22 | A |
Be the first to know about important NVNO news, forecast changes, insider trades & much more!
NVNO News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVNO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVNO ($10.50) is overvalued by 161.5% relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NVNO ($10.50) is not significantly undervalued (161.5%) relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NVNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NVNO due diligence checks available for Premium users.
Valuation
NVNO fair value
Fair Value of NVNO stock based on Discounted Cash Flow (DCF)
Price
$10.50
Fair Value
$4.02
Overvalued by
161.50%
NVNO ($10.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NVNO ($10.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NVNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
19.75x
Market
7.94x
NVNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.3x
Industry
2.92x
NVNO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVNO's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
NVNO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.1M
Liabilities
$2.4M
Debt to equity
0.1
NVNO's short-term assets ($25.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVNO's short-term assets ($25.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVNO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$2.8M
Financing
$0.0
NVNO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVNO vs Medical Device Stocks
Envveno Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.